期刊
MOLECULAR THERAPY
卷 21, 期 6, 页码 1151-1159出版社
CELL PRESS
DOI: 10.1038/mt.2013.56
关键词
-
资金
- Epidermolysis Bullosa Research Fund
- Jackson Gabriel Silver Foundation
- DebRA International
- University of Minnesota Academic Health Center
- Pioneering Unique Cures for Kids foundation
- Children's Cancer Research Fund
- Minneapolis
- Minnesota
- United States of America Department of Defense
- National Institutes of Health [R01 GM098861]
- National Institutes of Health Director's Pioneer Award [DP1 OD006862]
- Jim and Ann Orr MGH Research Scholar Award
- National Science Foundation
Recessive dystrophic epidermolysis bullosa (RDEB) is characterized by a functional deficit of type VII collagen protein due to gene defects in the type VII collagen gene (COL7A1). Gene augmentation therapies are promising, but run the risk of insertional mutagenesis. To abrogate this risk, we explored the possibility of using engineered transcription activator-like effector nucleases (TALEN) for precise genome editing. We report the ability of TALEN to induce site-specific double-stranded DNA breaks (DSBs) leading to homology-directed repair (HDR) from an exogenous donor template. This process resulted in COL7A1 gene mutation correction in primary fibroblasts that were subsequently reprogrammed into inducible pluripotent stem cells and showed normal protein expression and deposition in a teratoma-based skin model in vivo. Deep sequencing-based genome-wide screening established a safety profile showing on-target activity and three off-target (OT) loci that, importantly, were at least 10 kb from a coding sequence. This study provides proof-of-concept for TALEN-mediated in situ correction of an endogenous patient-specific gene mutation and used an unbiased screen for comprehensive TALEN target mapping that will cooperatively facilitate translational application.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据